[ad_1]
jetcityimage
Eli Lilly (NYSE:LLY) slashed the costs of the 2 lowest doses of its blockbuster weight reduction treatment Zepbound on Tuesday for purchases on its telehealth platform, LillyDirect.
Accordingly, a four-week provide of the GLP-1 receptor agonist shall be out there in a single vial format on LillyDirect for $399 and $549 at 2.5 mg and 5.0 mg doses, respectively. A four-week provide of Zepbound is at present out there in the marketplace for $1,060 in auto-injector pens.
“These new vials not only help us meet the high demand for our obesity medicine but also broaden access for patients seeking a safe and effective treatment option,” president of Lilly (LLY) USA, Patrik Jonsson, mentioned.
However, the brand new low-cost Zepbound variations marketed on LLY’s self-pay channel received’t be lined by insurance coverage.
“The self-pay channel enables a transparent price by removing third-party supply chain entities and allowing patients to access savings directly outside of insurance,” the corporate added.
Eli Lilly (LLY) and its rival within the weight reduction house, Novo Nordisk (NVO), have been going through provide constraints for his or her blockbuster weight problems drugs, tirzepatide and semaglutide, branded as Zepbound and Wegovy.
While the availability of some Wegovy doses continues to be restricted within the U.S., there aren’t any shortages of Zepbound doses, in accordance with the FDA.
“These new vials not only help us meet the high demand for our obesity medicine but also broaden access for patients seeking a safe and effective treatment option,” Jonsson added.
[ad_2]
Source: Seekingalpha